Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
MAP Ks act at the level of MST to
2022-01-07

MAP4Ks act at the level of MST1/2 to phosphorylate LATS1/2 and regulate the Hippo pathway (Box 1). Of particular interest is the involvement of MAP4K4, a key metabolic regulator [88] and common polymorphisms in the MAP4K4 locus are associated with T2D and insulin resistance [89] in adipogenesis. In
-
br Tissue Specific Roles for HIF PHD Isoforms Hypoxia signal
2022-01-07

Tissue-Specific Roles for HIF/PHD Isoforms Hypoxia signaling pathways are active in almost all mammalian cells, including immune TAE226 synthesis and tissues such as the epithelium and endothelium. This is of crucial importance when considering the influence of environmental hypoxia in inflammat
-
The Hardy Weinberg equilibrium was verified in all groups us
2022-01-07

The Hardy-Weinberg equilibrium was verified in all groups using the chi-square test. Using WINPEPI 11.65, the number of carriers and non-carriers of the Δ32 allele was compared between the groups through the Pearson's chi-square test with Yates's correction. Two-tailed Fisher's test was used when ap
-
Although it has been observed in numerous
2022-01-07

Although it has been observed in numerous studies and by many investigators that intraplatelet cGMP elevation results in platelet inhibition, there are a few papers which proposed a platelet stimulatory role for cGMP when elevated in response to NO donors or PDE5 inhibitors in mouse and human platel
-
The GPR receptor is also emerging as an
2022-01-06

The GPR55 receptor is also emerging as an important therapeutic target. GPR55−/− mice possess no overt phenotype, but were protected in models of inflammatory and neuropathic pain (Staton et al., 2008). Staton et al. (2008) reported that no GPR55 mRNA could be detected by RT-PCR in the animals. Also
-
Rofecoxib In both families GPR A mRNA in kidney fat was
2022-01-06

In both families, GPR109A mRNA in kidney fat was positively correlated with NEFA as a tendency. A positive correlation between this fat depot and insulin was observed in lean-type cows. In fat-type cows, mesenteric GPR109A mRNA correlated positively with insulin and negatively with urea on a moderat
-
Extending the issue of the species differences the role
2022-01-06

Extending the issue of the species differences, the role of neuroestradiol in the preovulatory GnRH/LH surge might be specific to primates or species with a luteal phase. For example, animals with a true luteal phase, such as monkeys and sheep, exhibit a long preovulatory GnRH surge, lasting well af
-
Here we reported series of carbohydrate modified
2022-01-06

Here, we reported series of carbohydrate-modified compounds containing a dibromo substituted benzene ring which was derived from the red alga (). The conformation flexibility of L-745,870 trihydrochloride and their polyol structures give them many unique biological properties as we have described ea
-
A group of small molecule with a more promising therapeutic
2022-01-06

A group of small molecule with a more promising therapeutic mechanism are known as γ-secretase modulators (GSMs), which modulate the cleavage activity of γ-secretase (and likely a host of other substrates) and specifically reduce the levels of the fibrillogenic Aβ42 peptide without altering the ε-si
-
Optimization of the tetrahydroindazole series led to the dis
2022-01-06

Optimization of the tetrahydroindazole series led to the discovery of two moderately potent γ-secretase modulators, 2-cyclobutane and 2-hydroxy-2-methylpropane which were subsequently evaluated in a kinetic aqueous solubility assay. Unfortunately, neither analog demonstrated improved solubility ()
-
Based upon the present findings it is tempting to imagine
2022-01-06

Based upon the present findings, it is tempting to imagine that selective, and especially stable blood–brain barrier (BBB) penetrating GalR1 antagonists might be useful as drugs for acute suppression of appetite. While this may be possible, previous studies using nonspecific galanin antagonists yiel
-
In summary this study demonstrated the cDNA
2022-01-06

In summary, this study demonstrated the cDNA cloning and characterization of the galanin type II receptor (GalR2) and a novel GalR2-like receptor (GalR2-L) in chickens, in which these two receptors are possibly originated from a gene Dantrolene, sodium salt event that occurred in the early vertebrat
-
br Discussion and concluding remarks FPR
2022-01-06

Discussion and concluding remarks FPR1 is considered to be a promising drug target for treating inflammatory and immunological diseases. Thus, natural compounds that could block and/or regulate FPR1 activity may be an important source of novel therapeutics for modulating inflammatory processes. H
-
As concerns TRPV assays benzylic amides and benzylic
2022-01-06

As concerns TRPV1 assays, benzylic amides and benzylic reverse amides exhibited an overall superiority over their aryl counterparts and , and ureas and . A reversed trend was however observed with the 4-chlorostyryl and 4--butylphenyl moieties (compare compounds and ; , , and ; and ). The EC a
-
br Acknowledgments The breast cancer laboratory is supported
2022-01-06

Acknowledgments The breast cancer laboratory is supported by the Australian National Health and Medical Research Council (NHMRC) grants no. 1016701, no. 1024852, no. 1086727; NHMRC IRIISS; the Victorian State Government through VCA funding of the Victorian Breast Cancer Research Consortium and Op
16086 records 538/1073 page Previous Next First page 上5页 536537538539540 下5页 Last page